value assessment

• 15th Sep 2025

  Value attributes of advanced therapy medicinal products: a comprehensive literature review

• 23rd Jun 2025

  The value of hope – the case against inclusion in a value assessment framework for advanced therapies 

• 28th Apr 2025

  Challenges and solutions to the sustainability of gene and cell therapies

• 10th Mar 2025

  A Perspective on ‘Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare Diseases’

• 7th Feb 2025

  Review of a ‘systematic review of challenges and opportunities in the implementation of managed entry agreements for advanced therapy medicinal products’

• 2nd Sep 2024

  A case study of the challenges of demonstrating cost-effectiveness in under-served patient populations: lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease

• 17th Jun 2024

  Identifying value elements of advanced therapy medicinal products: An opportunistic review of stakeholder responses submitted to NICE as part of reimbursement decision making